Jci_page_head_homepage_01 Jci_page_head_homepage_02
Jeffrey E. Galvin, Mark E. Hemric, Kent Ward, Madeleine W. Cunningham
Published in Volume 106, Issue 2
J Clin Invest. 2000; 106(2):217–224 doi:10.1172/JCI7132
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 7

Competitive inhibition of mAb 3.B6 reactivity with human valve tissue sections. (a) Illustrates the reaction of mAb 3.B6 with valve endothelium and underlying matrix; (b) inhibition of mAb 3.B6 by HCM; (c) inhibition of mAb 3.B6 by laminin; (d) very weak inhibition by GlcNAc-BSA, whereas inhibition with BSA alone (not shown) was equivalent to Figure 7a; (e) no inhibition by laminin A-chain peptide DRDQLM (residues 655–660); (f) inhibition by laminin A-chain peptide HTQNT (residues 1002–1006). Reactivity of mAb 3.B6 against human valve was inhibited by cardiac myosin > laminin > GlcNAc, and laminin A-chain peptide HTQNT inhibited > laminin A-chain peptide DRDQLM.